<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29211222</article-id><article-id pub-id-type="pmc">5701106</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0081</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>CABG Surgery Remains the best Option for Patients with Left Main
Coronary Disease in Comparison with PCI-DES: Meta-Analysis of Randomized
Controlled Trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>S&#x000e1;</surname><given-names>Michel Pompeu Barros Oliveira</given-names></name><degrees>MD, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Soares</surname><given-names>Artur Freire</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Miranda</surname><given-names>Rodrigo Gusm&#x000e3;o Albuquerque</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ara&#x000fa;jo</surname><given-names>Mayara Lopes</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Menezes</surname><given-names>Alexandre Motta</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Frederico Pires Vasconcelos</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Ricardo Carvalho</given-names></name><degrees>MD, MSc, PhD, ChM</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Division of Cardiovascular Surgery, Pronto-Socorro
Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Recife, PE, Brazil.</aff><aff id="aff2">
<label>2</label> Universidade de Pernambuco (UPE), Recife, PE, Brazil.</aff><aff id="aff3">
<label>3</label> Nucleus of Postgraduate and Research in Health Sciences of
Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas de Pernambuco/Instituto de
Ci&#x000ea;ncias Biol&#x000f3;gicas (FCM/ICB), Recife, PE, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: Michel Pompeu Barros Oliveira S&#x000e1;,
Pronto-Socorro Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Rua dos Palmares S/N
- Santo Amaro - Recife, PE, Brazil - Zip code: 74970-240. E-mail:
<email>michel_pompeu@yahoo.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2017</year></pub-date><volume>32</volume><issue>5</issue><fpage>408</fpage><lpage>416</lpage><history><date date-type="received"><day>15</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To compare the safety and efficacy of coronary artery bypass grafting (CABG)
with percutaneous coronary intervention (PCI) using drug-eluting stents
(DES) in patients with unprotected left main coronary artery (ULMCA)
disease.</p></sec><sec><title>Methods</title><p>MEDLINE, EMBASE, CENTRAL/CCTR, SciELO, LILACS, Google Scholar and reference
lists of relevant articles were searched for clinical studies that reported
outcomes at 1-year follow-up after PCI with DES and CABG for the treatment
of ULMCA stenosis. Five studies fulfilled our eligibility criteria and they
included a total of 4.595 patients (2.298 for CABG and 2.297 for PCI with
DES).</p></sec><sec><title>Results</title><p>At 1-year follow-up, there was no significant difference between CABG and DES
groups concerning the risk for death (risk ratio [RR] 0.973,
<italic>P</italic>=0.830), myocardial infarction (RR 0.694,
<italic>P</italic>=0.148), stroke (RR 1.224, <italic>P</italic>=0.598),
and major adverse cerebrovascular and cardiovascular events (RR 0.948,
<italic>P</italic>=0.680). The risk for target vessel revascularization
(TVR) was significantly lower in the CABG group compared to the DES group
(RR 0.583, <italic>P</italic>&#x0003c;0.001). It was observed no publication bias
regarding the outcomes, but only the outcome TVR was free from substantial
statistical heterogeneity of the effects. In the meta-regression, there was
evidence that the factor "female gender" modulated the effect regarding
myocardial infarction rates, favoring the CABG strategy.</p></sec><sec><title>Conclusion</title><p>CABG surgery remains the best option of treatment for patients with ULMCA
disease, with lower TVR rates.</p></sec></abstract><kwd-group><kwd>Meta-Analysis</kwd><kwd>Drug-Eluting Stents</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Stents</kwd><kwd>Percutaneous Coronary Intervention</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="36%" span="1"/><col width="8%" span="1"/><col width="10%" span="1"/><col width="36%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Bare-metal stent</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MeSH</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Medical Subject
Heading</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Myocardial
infarction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CENTRAL/CCTR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cochrane Central
Register of Controlled Trials</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Non-reported</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CK-MB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Creatine kinase-MB</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diameter stenosis</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI-DES</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention/Drug-eluting stent</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FFR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Fractional flow
reserve</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PICOS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Population,
Intervention, Comparison, Outcome and Study Design</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hazard ratio</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PRISMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Preferred Reporting
Items for Systematic Reviews and Meta-Analyses</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IVUS MLA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intravascular ultrasound
minimal lumen area</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RCTs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Randomized controlled
trials</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">JACC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Journal of the American
College of Cardiology</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Risk ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left anterior
descending</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SciELO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Scientific Electronic
Library Online</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LCX</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left circumflex
artery</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LILACS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Latin American and
Caribbean Health Sciences Literature</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard error</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left main</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Target vessel
revascularization</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MACCE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Major adverse
cerebrovascular and cardiovascular events</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ULMCA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Unprotected left main
coronary artery</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><sec><title>Rationale</title><p>The current international revascularization guidelines recommend
revascularization of unprotected left main coronary artery (ULMCA) with coronary
artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in
subjects with low (&#x0003c;23: class I, recommendation for CABG or PCI - level of
evidence B) and intermediate (23-32: class I for CABG and class IIa for PCI -
level of evidence B) SYNTAX scores. The same guidelines recommend against
revascularization with PCI of ULMCA disease with high SYNTAX scores (&#x02265;33:
class I for CABG and class III for PCI - level of evidence B)<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Capodanno et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup> published a meta-analysis of
randomized controlled trials (RCTs) and suggested, boldly, that "based on their
study, revision of the guidelines regarding left main PCI is warranted, raising
the level of evidence of current recommendations from B to A". Although some
RCTs have suggested that PCI with drug-eluting stent (DES) could be a
non-inferior strategy which might be used safely<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>, sample
sizes were not so large (and some conclusions may have been affected by this
factor). Recently, the trials EXCEL<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> and NOBLE<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> were published, which led us to revisit the literature and
carry out a new meta-analysis.</p></sec><sec><title>Objective</title><p>We performed a meta-analysis of RCTs to compare CABG to PCI with DES for the
treatment of patients with ULMCA disease, according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p></sec></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Eligibility Criteria</title><p>Using Population, Intervention, Comparison, Outcome and Study Design (PICOS)
strategy, studies were considered eligible if: (1) the population comprised
patients with ULMCA disease; (2) there was compared efficacy between CABG and
PCI with DES; (3) the studied outcomes have included death, myocardial
infarction (MI), stroke, target vessel revascularization (TVR) or major adverse
cerebrovascular and cardiovascular events (MACCE); (4) there was a follow-up of
at least 12 months. There was no restriction on language.</p></sec><sec><title>Information Sources</title><p>The following databases were used (until December 2016): MEDLINE, EMBASE,
Cochrane Central Register of Controlled Trials (CENTRAL/CCTR),
ClinicalTrials.gov, Scientific Electronic Library Online (SciELO), Latin
American and Caribbean Health Sciences Literature (LILACS), Google Scholar, and
reference lists of relevant articles.</p></sec><sec><title>Search</title><p>We conducted the search using Medical Subject Heading (MeSH) terms: ["coronary
artery bypass graft" OR "coronary artery bypass grafting" OR "coronary artery
bypass surgery" OR "coronary bypass surgery" OR "coronary artery bypass graft
surgery" OR "coronary artery bypass" OR "coronary bypass"] AND ["drug-eluting
stent" OR "sirolimus-eluting stent" OR "paclitaxel-eluting stent" OR
"everolimus-eluting stent" OR "biolimus-eluting stent"] AND ["unprotected left
main" OR "left main stenting" OR "left main coronary artery disease" OR "left
main PCI" OR "unprotected left main coronary artery" OR "left main stenosis" OR
"left main coronary artery stenting" OR "unprotected left main stenting"].</p></sec><sec><title>Study Selection</title><p>The following steps were taken: (1) identification of titles of records through
database searching; (2) removal of duplicates; (3) screening and selection of
abstracts; (4) assessment for eligibility through full-text articles; (5) final
inclusion in the study.</p><p>One reviewer followed the steps 1 to 3. Two independent reviewers followed the
step 4 and selected studies. Inclusion or exclusion of studies was decided
unanimously. When there was disagreement, a third reviewer took the final
decision.</p></sec><sec><title>Data Items</title><p>The primary endpoint was the risk ratio (RR) for mortality after PCI-DES or CABG,
up to 12 months. Secondary endpoints were the RR for MI, stroke, TVR after the
procedure, and MACCE (composite endpoint of death, MI, stroke or TVR).</p></sec><sec><title>Data Collection Process</title><p>Two independent reviewers extracted the data. When there was disagreement about
it, a third reviewer (the first author) checked the data and made the final
decision. From each study, we extracted patients' characteristics, study design,
and outcomes at 1 year after treatment of ULMCA stenosis. Alternatively,
probabilities of mortality or MACCE were estimated from published Kaplan-Meier
survival curves. When it was possible, we also extracted TVR from the total
MACCE events and reported this outcome as a separate measure. When MACCE had not
been reported, we calculated it using the events of death, MI, stroke and TVR,
and reported this outcome as a separate measure.</p></sec><sec><title>Risk of Bias in Individual Studies</title><p>Included studies were assessed for the following characteristics: sequence
generation (randomization); allocation concealment (selection bias); blinding of
participants and personnel (performance bias); blinding of outcome assessors
(detection bias) and incomplete outcome data addressed (attrition
bias)<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>Taking these characteristics into account, the papers were classified in A (low
risk of bias), B (moderate risk of bias), C (high risk of bias) or D (unclear).
Two independent reviewers evaluated the risk of bias. Agreement between the two
reviewers was assessed with Kappa statistics for full-text screening and rating
of relevance and risk of bias. When there was disagreement about risk of bias, a
third reviewer checked the data and made the final decision.</p></sec><sec><title>Summary Measures</title><p>The principal summary measures were RRs with 95% confidence interval (CI) and
<italic>P</italic> values (statistically significant when &#x0003c;0.05). The
meta-analysis was completed using the software Comprehensive Meta-Analysis
version 2 (Biostat Inc., Englewood, NJ, USA).</p></sec><sec><title>Synthesis of Results</title><p>Forest plots were generated for graphical presentations for clinical outcomes and
we have performed the I-squared test and Chi statistics for assessment of
heterogeneity across the studies<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Each study was summarized by the RR for PCI-DES compared
to CABG. The RRs were combined across studies using DerSimonian-Laird random
effects model<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>, weighted by
number of events in each study.</p></sec><sec><title>Risk of Bias Across Studies</title><p>To assess publication bias, a funnel plot was generated (for each outcome), being
statistically evaluated by Begg and Mazumdar's test<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> and Egger's test<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p></sec><sec><title>Sensitivity Analysis</title><p>We investigated the influence of a single study on the overall effect - by
sequentially removing one study - to test the robustness of the main results, so
we could verify whether any study had an excessive influence on the overall
results or not.</p></sec><sec><title>Meta-regression Analysis</title><p>Meta-regression analyses were performed to determine if the effects of CABG were
modulated by pre-specified factors. Meta-regression graphs describe the effect
of CABG on the outcome (plotted as a log RR on the y-axis) as a function of a
given factor (plotted as a mean or proportion of that factor on the x-axis).
Meta-regression coefficients show the estimated increase in log RR per unit
increase in the covariate. Since log RR &#x0003e; 0 corresponds to RR &#x0003e; 1 and log
RR &#x0003c; 0 corresponds to RR &#x0003c; 1, a negative coefficient will indicate that
when a given factor increases, the OR decreases.</p><p>The predetermined modulating factors to be examined were: age (mean), female
gender (%), diabetes (%), smoke (%), hypertension (%), SYNTAX score (mean) and
distal left main lesion (%). This choice was made based on the factors that
could recognizably modulate the summary measures when it comes to ULMCA disease.
For studies reporting interquartile ranges, the mean was estimated according to
the formula [minimum+maximum+2(median)]/4 and the standard deviation (SD) was
calculated based on the formula (maximum-minimum)/6<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study Selection</title><p>A total of 14.885 citations were identified, of which 32 studies seemed to be
potentially relevant and were retrieved as full-texts. Five publications
fulfilled our eligibility criteria<sup>[<xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Interobserver reliability of study relevance
was excellent (Kappa=0.83). Agreement for decisions related to study validity
was very good (Kappa=0.80). The search strategy can be seen in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow diagram of studies included in data search.</p><p>BMS=bare-metal stents; CABG=coronary artery bypass grafting;
CENTRAL/CCTR=Cochrane Central Register of Controlled Trials;
LILACS=Latin American and Caribbean Health Sciences Literature;
PCI-DES=percutaneous coronary intervention/drug-eluting stent;
RCT=randomized controlled trial; SciELO=Scientific Electronic
Library Online</p></caption><graphic xlink:href="rbccv-32-05-0408-g01"/></fig>
</p></sec><sec><title>Study Characteristics</title><p>Characteristics of each study are shown in <xref ref-type="table" rid="t1">Table
1</xref>. A total of 4.595 patients were studied, with 2.298 receiving CABG
and 2.297 receiving PCI with DES, during the years of 2003 to 2016. Two
studies<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup> mostly used Cypher stent
(sirolimus), one<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> used Taxus
stent (paclitaxel), one<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> used
Xience stent (everolimus) and one<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> predominantly used Biomatrix Flex stent (biolimus; the
latter was the recommended study stent but other "Conformit&#x000e9;
Europ&#x000e9;ene-marked" DES could be used at the operators' discretion). The
overall internal validity was moderate and is illustrated in <xref ref-type="table" rid="t2">Table 2</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Study characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">PCI (n)</th><th align="center" rowspan="1" colspan="1">DES</th><th align="center" rowspan="1" colspan="1">Complete revascu-larization with PCI (%)</th><th align="center" rowspan="1" colspan="1">CABG (n)</th><th align="center" rowspan="1" colspan="1">LIMA to LAD (%)</th><th align="center" rowspan="1" colspan="1">Off-pump (%)</th><th align="center" rowspan="1" colspan="1">Complete revascu-larization with CABG (%)</th><th align="center" rowspan="1" colspan="1">Age (PCI/CABG) (years/mean)</th><th align="center" rowspan="1" colspan="1">Diabetes mellitus (PCI/CABG) (%)</th><th align="center" rowspan="1" colspan="1">SYNTAX score (PCI/CABG) (mean)</th><th align="center" rowspan="1" colspan="1">EuroSCORE (PCI/CABG) (mean)</th><th align="center" rowspan="1" colspan="1">Years</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">EXCEL trial<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup></td><td align="center" rowspan="1" colspan="1">948</td><td align="center" rowspan="1" colspan="1">Xience (100%)</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">957</td><td align="center" rowspan="1" colspan="1">98.8</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">66/66</td><td align="center" rowspan="1" colspan="1">30/28</td><td align="center" rowspan="1" colspan="1">21/21</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">2010-2016</td></tr><tr><td align="center" rowspan="1" colspan="1">NOBLE trial<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup></td><td align="center" rowspan="1" colspan="1">592</td><td align="center" rowspan="1" colspan="1">Biomatrix Flex (predominantly)</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">592</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">66/66</td><td align="center" rowspan="1" colspan="1">15/15</td><td align="center" rowspan="1" colspan="1">23/22</td><td align="center" rowspan="1" colspan="1">2/2</td><td align="center" rowspan="1" colspan="1">2008-2015</td></tr><tr><td align="center" rowspan="1" colspan="1">PRECOMBAT trial<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup></td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">Cypher (100%)</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">93.6</td><td align="center" rowspan="1" colspan="1">63.8</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">62/63</td><td align="center" rowspan="1" colspan="1">34/30</td><td align="center" rowspan="1" colspan="1">24/26</td><td align="center" rowspan="1" colspan="1">2.6/2.8</td><td align="center" rowspan="1" colspan="1">2004-2009</td></tr><tr><td align="center" rowspan="1" colspan="1">SYNTAX trial<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup></td><td align="center" rowspan="1" colspan="1">357</td><td align="center" rowspan="1" colspan="1">Taxus (100%)</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">348</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">66/65</td><td align="center" rowspan="1" colspan="1">24/26</td><td align="center" rowspan="1" colspan="1">30/30</td><td align="center" rowspan="1" colspan="1">3.9/3.9</td><td align="center" rowspan="1" colspan="1">2005-2007</td></tr><tr><td align="center" rowspan="1" colspan="1">Boudriot et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>2011</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">Cypher (98%)Taxus (2%)</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">66/69</td><td align="center" rowspan="1" colspan="1">40/30</td><td align="center" rowspan="1" colspan="1">24/23</td><td align="center" rowspan="1" colspan="1">2.4/2.6</td><td align="center" rowspan="1" colspan="1">2003-2009</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Biomatrix Flex: Biolimus-eluting stent; Cypher: sirolimus-eluting
stent; Taxus: paclitaxel-eluting stent; Xience: everolimus-eluting
stent.</p><p>CABG=coronary artery bypass grafting; DES=drug-eluting stent;
LAD=left anterior descending artery; LIMA=left internal mammary
artery; PCI=percutaneous coronary intervention; NR =
non-reported</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Analysis of risk of bias &#x02013; internal validity.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Selection bias</th><th align="center" rowspan="1" colspan="1">Performance bias</th><th align="center" rowspan="1" colspan="1">Attrition bias</th><th align="center" rowspan="1" colspan="1">Detection bias</th><th align="center" rowspan="1" colspan="1">Multivariate adjustment for possible
confounders</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">EXCEL trial<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup></td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">Probably adequate</td></tr><tr><td align="left" rowspan="1" colspan="1">NOBLE trial<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup></td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">Probably adequate</td></tr><tr><td align="left" rowspan="1" colspan="1">PRECOMBAT trial<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup></td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">Probably adequate</td></tr><tr><td align="left" rowspan="1" colspan="1">SYNTAX trial<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup></td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">D</td><td align="center" rowspan="1" colspan="1">Probably adequate</td></tr><tr><td align="left" rowspan="1" colspan="1">Boudriot et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>2011</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">Probably adequate</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>A=risk of bias is low; B=risk of bias is moderate; C=risk of bias is
high; D=unclear to determine</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Synthesis of Results</title><p>The RR for death in the CABG group compared with that in the PCI-DES group in
each study, at 1-year time point, is reported in <xref ref-type="fig" rid="f2">Figure 2A</xref>. There was evidence of moderate heterogeneity of treatment
effect among the studies for death. The overall RR (95% CI) of death showed no
difference between CABG and PCI-DES at 1-year (random effect model: RR 0.973,
<italic>P</italic>=0.830).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Risk ratio (RR) and conclusions plot of death, myocardial infarction
(MI), stroke, target vessel revascularization (TVR), and major
adverse cerebrovascular and cardiovascular events (MACCE) associated
with coronary artery bypass grafting (CABG) vs. percutaneous
coronary intervention/drug-eluting stent (PCI-DES).</p><p>CI=Confidence interval</p></caption><graphic xlink:href="rbccv-32-05-0408-g02"/></fig>
</p><p>The RR for MI in the CABG group compared with that in the PCI-DES group in each
study, at 1-year time point, is reported in <xref ref-type="fig" rid="f2">Figure
2B</xref>. There was evidence of substantial heterogeneity of treatment
effect among the studies for MI. The overall RR (95% CI) for MI showed no
difference between CABG and PCI-DES at 1-year (random effect model: RR 0.694,
<italic>P</italic>=0.148).</p><p>The RR for stroke in the CABG group compared with that in the PCI-DES group in
each study, at 1-year time point, is reported in <xref ref-type="fig" rid="f2">Figure 2C</xref>. There was evidence of substantial heterogeneity of
treatment effect among the studies for stroke. The overall RR (95% CI) for
stroke showed no difference between CABG and PCI-DES at 1-year (random effect
model: RR 1.224, <italic>P</italic>=0.598).</p><p>The RR for TVR in the CABG group compared with that in the PCI-DES group in each
study, at 1-year time point, is reported in <xref ref-type="fig" rid="f2">Figure
2D</xref>. There was no evidence of heterogeneity of treatment effect among
the studies for TVR. The overall RR (95% CI) for TVR showed a statistically
significant difference between CABG and PCI-DES at 1-year, favoring CABG (random
effect model: RR 0.583, <italic>P</italic>&#x0003c;0.001).</p><p>The RR for MACCE in the CABG group compared with that in the PCI-DES group in
each study, at 1-year time point, is reported in <xref ref-type="fig" rid="f2">Figure 2E</xref>. There was evidence of substantial heterogeneity of
treatment effect among the studies for MACCE. The overall RR (95% CI) for MACCE
showed no difference between CABG and PCI-DES at 1-year (random effect model: RR
0.948, <italic>P</italic>=0.680).</p></sec><sec><title>Risk of Bias Across Studies</title><p>Funnel plot analysis (<xref ref-type="fig" rid="f3">Figure 3</xref>) disclosed no
asymmetry around the axis for the treatment effect when the outcomes were
analyzed, which means we probably have no publication bias related to these
outcomes.</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Publication bias analysis by funnel plot graphic.</p><p>MACCE=Major adverse cerebrovascular and cardiovascular events</p></caption><graphic xlink:href="rbccv-32-05-0408-g03"/></fig>
</p></sec><sec><title>Sensitivity Analysis</title><p>Sensitivity analyses performed by removing each single study from the
meta-analysis to determine the influence of an individual data set to the pooled
RR showed that the EXCEL trial caused a major change in direction/magnitude of
statistical findings regarding the outcome MI (<xref ref-type="fig" rid="f4">Figure 4B</xref>). When this study was removed from the analysis, a
statistically significant difference in favor of CABG appeared, which means that
this study actually had an excessive influence on the overall results concerning
the outcome MI, favoring excessively the PCI-DES when it was included.</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Sensitivity analyses (one study removed).</p><p>CABG=coronary artery bypass grafting; CI=confidence interval;
MACCE=major adverse cerebrovascular and cardiovascular events;
PCI-DES=percutaneous coronary intervention/drug-eluting stent</p></caption><graphic xlink:href="rbccv-32-05-0408-g04"/></fig>
</p></sec><sec><title>Meta-regression Analysis</title><p>Meta-regression coefficients were not statistically significant for age,
diabetes, smoke, hypertension, SYNTAX score or distal left main lesion, which
means that none of these evaluated factors had any modulation influence on the
final effect, regarding death, MI, stroke, TVR or MACCE. When we analyzed the
outcome "MI" and the pre-determined factor "female gender", it was observed a
statistically significant coefficient for proportion of female patients and RR
for MI (coefficient -0.42; 95% CI -0.73 to 0.11; <italic>P</italic>=0.007; <xref ref-type="fig" rid="f5">Figure 5</xref>). We can observe that the greater
the proportion of female patients, the lower the RR for MI in the group CABG in
comparison to PCI-DES group.</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Meta-regression analysis.</p><p>CI=confidence interval; SE=standard error</p></caption><graphic xlink:href="rbccv-32-05-0408-g05"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec><title>Summary of Evidence</title><p>The results of this meta-analysis demonstrate that PCI with DES for ULMCA disease
presents a significantly higher risk for TVR at 1-year follow-up in comparison
to CABG, being this outcome under no influence of statistical heterogeneity or
publication bias. Although there was no difference in the risk for death, MI,
stroke and MACCE, these summary measures were underpowered by heterogeneity of
the effects.</p><p>We've also observed that the EXCEL trial had had a major influence on the overall
results regarding the outcome MI, favoring excessively the group PCI-DES.
Interestingly, as evidenced by the meta-regression analysis, the gender seems to
play a certain role in the results, since we've detected that when there were
more women in the group CABG, more beneficial was this strategy in comparison to
PCI with-DES.</p></sec><sec><title>Considerations</title><p>The length of follow-up considered for this study may have been too short (1
year) to truly detect differences between the treatment groups. CABG is
associated with a higher early mortality rate from perioperative complications,
and it is possible that with a longer follow-up, CABG patients may have an
improved survival rate compared to patients undergoing PCI with DES. Curiously,
we've observed no statistically significant difference regarding the outcome
stroke, although we had expected a higher risk in the CABG group. The long-term
durability of PCI <italic>vs.</italic> CABG remains undetermined and will
require studies with longer follow-ups to produce a robust meta-analysis of
long-term results. Up to now, only SYNTAX, PRECOMBAT and NOBLE trials published
their 5-year follow-ups.</p><p>Regarding the major influence on the overall rate of MI exerted by the EXCEL
trial, favoring excessively the group PCI-DES, we must bear in mind that this
study excluded patients with SYNTAX score &#x02265;33. On the other hand, the
NOBLE trial has enrolled patients with ostium, mid-shaft and/or bifurcation and
with no more than three additional non-complex PCI lesions, defined as length
&#x0003c;25 mm, non-chronic total occlusion, non-two-stent bifurcation, non-calcified
and non-tortuous coronary lesions.</p><p>The gender seemed to play a certain role in the results. Intriguingly, there are
studies showing that women experience higher short-term and long-term mortality
rates after PCI compared to men<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> and showing that women have worse longterm outcomes after
CABG than men<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. To sum up,
women tend to benefit less from both invasive strategies. Nevertheless, when it
comes to comparing CABG with PCI-DES, it seems that the former presents better
results, since studies showed that CABG may provide the greatest benefit to
patients who have most extensive heart disease<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>,
maybe because women (compared with men) are, on average, older and more likely
to have diabetes and hypertension and to present for surgery with urgent/
emergent status<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>One of the limitations is the heterogeneity of the strategies across the studies.
Among PCI strategies, some studies used either only sirolimus-stent or only
paclitaxel-stents or predominantly biolimus-stents or only everolimus-stents,
and some mixed drug-eluting stents, etc. Campos et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> underlined some differences
about how the Heart Team assessed the ULMCA as being significant in the studies.
For example, the NOBLE trial adopted as significant an ULMCA with a visually
assessed DS&#x0003e;50% or a fractional flow reserve (FFR) &#x0003c;0.80. The EXCEL trial
defined significant ULMCA as one of the following: DS&#x02265;70% (visually
estimated) or DS&#x02265;50% but &#x0003c;70% (requiring non-invasive or invasive [FFR
&#x02264;0.80] evidence of ischaemia or intravascular ultrasound minimal lumen
area [IVUS MLA] &#x02264;6.0 mm<sup>2</sup>). Additionally, the EXCEL trial has
enrolled patients with a left main equivalent disease, defined as bifurcation
disease, with both the ostial left anterior descending (LAD) artery and ostial
left circumflex artery (LCX) stenoses having &#x02265;70% DS. If one or both
ostial LAD and ostial LCX stenoses are &#x02265;50% and &#x0003c;70% stenotic by
visual estimation, then this(ese) lesion(s) is(are) demonstrated to be
significant either by non-invasive or invasive (FFR &#x02264;0.80) evidence of
ischaemia in its myocardial distribution or IVUS MLA &#x02264;4.0 mm<sup>2</sup>.
By protocol, in EXCEL, FFR was the preferred strategy to stratify lesion
significance. Among CABG strategies, there is variability in rates of use of
internal thoracic artery, use of cardiopulmonary bypass (on-pump
<italic>vs.</italic> off-pump CABG), etc. And between both strategies, an
important aspect to consider is the rate of complete revascularization (that was
not reported adequately in 2 studies<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>, but in the 2
studies<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup> that reported these rates, both
arms presented high rates of incomplete revascularization, reaching around 30%),
which reflects in the outcomes.</p><p>Curiously, the publication of EXCEL and NOBLE trials, both studying the same
issue and emerging with different results, may have confused some cardiologists
and cardiovascular surgeons. In the EXCEL study, investigators randomized 948
patients with ULMCA disease to PCI with Xience and 957 patients to CABG surgery.
The primary endpoint-a composite that included allcause mortality, stroke, or MI
at 3 years-occurred in 15.4% of patients treated with PCI and 14.7% of patients
treated with CABG (<italic>P</italic>=0.02 for non-inferiority). The researchers
also analyzed data at the 30<sup>th</sup> day, a secondary endpoint. The rate of
death, stroke or MI was significantly higher among the CABG-treated patients
(4.9% <italic>vs.</italic> 7.9%; HR 0.61; 95% CI 0.42-0.88), and this difference
was driven by a considerably increased risk of MI (3.9% <italic>vs.</italic>
6.2%; HR 0.63; 95% CI 0.42-0.95). In particular, there was a significantly
increased risk of "large" periprocedural MI with CABG, which was defined as
CK-MB more than 10 times the upper limit of normal (or 5 times the upper limit
of normal plus other evidence of MI). In the NOBLE trial, 1,201 patients with
ULMCA disease were randomized to PCI or CABG. The 5-year estimate of MACCE-a
composite of all-cause mortality, nonprocedural MI, any repeat coronary
revascularization, and stroke-occurred in 29% of patients treated with PCI and
19% of patients who underwent CABG, a difference that exceeded the limit for
non-inferiority (<italic>P</italic>=0.007 for superiority). Therefore, the
results of these studies are clearly conflicting.</p><p>There are inherent limitations in meta-analyses, including the use of cumulative
data from summary estimates. Patients' data were gathered from published data,
not from individual patient follow-up. Access to individual patient's data would
have enabled us to conduct further subgroup analysis and propensity analysis to
account for differences between the treatment groups. This meta-analysis
included only data from randomized studies, which do not reflect the "real
world" but, on the other hand, are less limited by publication bias, treatment
bias, confounders, and a certain tendency to overestimate the treatment effects
observed in observational studies, since patients' selection alters the outcomes
and thus makes non-randomized studies less robust.</p><p>A final limitation is the absence of adequate published comparative data for the
third therapeutic option, medical therapy. PCI with DES has not been compared
yet with medical therapy alone when we consider ULMCA disease, but CABG has been
shown to be superior to medical therapy in this set.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>We found evidence that argues against the so-called "non-inferiority" of PCI with DES
in comparison to CABG surgery and against the idea that PCI can be considered a
reasonable choice in elective cases (not mentioning prohibitive risk patients, acute
patients, and those who reject surgery). Given that, although the rates of death,
MI, stroke, and MACCE between both strategies were not statistically different
(remembering the heterogeneity related to these outcomes), the need of new
procedures were clearly lower in patients treated with CABG surgery. However,
careful analysis of the data shows that no definite conclusion can be drawn from the
evidence available due to the heterogeneity of studies regarding the outcomes,
heterogeneity of strategies (different drug-eluting stents, different ways to
perform surgery, etc), and heterogeneity of coronary lesions complexity.</p><p>Needless to say, we are living in a changing world. It is incredible how fast the
winds of change blow through the medical literature. Nowadays, an author publishes a
meta-analysis boldly recommending changing the level of evidence of PCI-DES in ULMCA
patients in the Journal of the American College of Cardiology (JACC), a high-quality
journal, and then, after new evidence came out, the same author changes his/her
stance on this issue one more time. New data will come when we have the 5-year
results of these trials, when the scientific community will be enlightened with
stronger and definitive results. Disagreeing with other authors, we conclude that
"based on our study, revision of the guidelines regarding left main PCI with DES
must be viewed with caution, and we still do not have enough evidence that makes the
level of evidence of current recommendations raises from B to A".</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" valign="top" rowspan="1">Authors' roles &#x00026;
responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">MPBOS</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and study design; data
management; manuscript redaction or critical review of its content;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AFS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RGAM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MLA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AMM</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and study design; data
management; manuscript redaction or critical review of its content;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FPVS</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and study design; data
management; manuscript redaction or critical review of its content;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RCL</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and study design; data
management; manuscript redaction or critical review of its content;
final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Division of Cardiovascular Surgery,
Pronto-Socorro Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Recife, PE,
Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Alfonso</surname><given-names>F</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Cremer</surname><given-names>J</given-names></name><name><surname>Falk</surname><given-names>V</given-names></name><etal/></person-group><article-title>2014 ESC/EACTS Guidelines on myocardial revascularization: the
task force on myocardial revascularization of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS) Developed with the special contribution of the European Association
of Percutaneous Cardiovascular Interventions (EAPCI)</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><issue>37</issue><fpage>2541</fpage><lpage>2619</lpage><pub-id pub-id-type="pmid">25173339</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Bass</surname><given-names>TA</given-names></name><name><surname>Tamburino</surname><given-names>C</given-names></name></person-group><article-title>Percutaneous coronary intervention versus coronary artery bypass
graft surgery in left main coronary artery disease. A meta-analysis of
randomized clinical data</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>58</volume><issue>14</issue><fpage>1426</fpage><lpage>1432</lpage><pub-id pub-id-type="pmid">21939824</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>DW</given-names></name><name><surname>Yun</surname><given-names>SC</given-names></name><name><surname>Ahn</surname><given-names>JM</given-names></name><name><surname>Song</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Randomized trial of stents versus bypass surgery for left main
coronary artery disease</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>18</issue><fpage>1718</fpage><lpage>1727</lpage><pub-id pub-id-type="pmid">21463149</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><etal/><collab>SYNTAX Investigators</collab></person-group><article-title>Percutaneous coronary intervention versus coronary-artery bypass
grafting for severe coronary artery disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>10</issue><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">19228612</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Sabik</surname><given-names>JF</given-names></name><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Simonton</surname><given-names>CA</given-names></name><name><surname>G&#x000e9;n&#x000e9;reux</surname><given-names>P</given-names></name><name><surname>Puskas</surname><given-names>J</given-names></name><etal/><collab>EXCEL Trial Investigators</collab></person-group><article-title>Everolimus-eluting stents or bypass surgery for left main
coronary artery disease</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>23</issue><fpage>2223</fpage><lpage>2235</lpage><pub-id pub-id-type="pmid">27797291</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;kikallio</surname><given-names>T</given-names></name><name><surname>Holm</surname><given-names>NR</given-names></name><name><surname>Lindsay</surname><given-names>M</given-names></name><name><surname>Spence</surname><given-names>MS</given-names></name><name><surname>Erglis</surname><given-names>A</given-names></name><name><surname>Menown</surname><given-names>IB</given-names></name><etal/><collab>NOBLE study investigators</collab></person-group><article-title>Percutaneous coronary angioplasty versus coronary artery bypass
grafting in treatment of unprotected left main stenosis (NOBLE): a
prospective, randomised, open-label, non-inferiority trial</article-title><source>Lancet</source><year>2016</year><volume>388</volume><issue>10061</issue><fpage>2743</fpage><lpage>2752</lpage><pub-id pub-id-type="pmid">27810312</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>PRISMA Group</collab></person-group><article-title>Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement</article-title><source>Ann Intern Med</source><year>2009</year><volume>151</volume><issue>4</issue><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">19622511</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><chapter-title>Assessing risk of bias in included studies</chapter-title><person-group person-group-type="editor"><name><surname>Higgins</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>S</given-names></name></person-group><source>Cochrane handbook for systematic reviews of interventions. Version
5.0</source><publisher-name>The Cochrane Collaboration</publisher-name><year>2008</year></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12958120</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Kacker</surname><given-names>R</given-names></name></person-group><article-title>Random-effects model for meta-analysis of clinical trials: an
update</article-title><source>Contemp Clin Trials</source><year>2007</year><volume>28</volume><issue>2</issue><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">16807131</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>CB</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name></person-group><article-title>Operating characteristics of a rank correlation test for
publication bias</article-title><source>Biometrics</source><year>1994</year><volume>50</volume><issue>4</issue><fpage>1088</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">7786990</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical
test</article-title><source>BMJ</source><year>1997</year><volume>315</volume><issue>7109</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">9310563</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hozo</surname><given-names>SP</given-names></name><name><surname>Djulbegovic</surname><given-names>B</given-names></name><name><surname>Hozo</surname><given-names>I</given-names></name></person-group><article-title>Estimating the mean and variance from the median, range, and the
size of a sample</article-title><source>BMC Med Res Methodol</source><year>2005</year><volume>5</volume><fpage>13</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15840177</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudriot</surname><given-names>E</given-names></name><name><surname>Thiele</surname><given-names>H</given-names></name><name><surname>Walther</surname><given-names>T</given-names></name><name><surname>Liebetrau</surname><given-names>C</given-names></name><name><surname>Boeckstegers</surname><given-names>P</given-names></name><name><surname>Pohl</surname><given-names>T</given-names></name><etal/></person-group><article-title>Randomized comparison of percutaneous coronary intervention with
sirolimus-eluting stents versus coronary artery bypass grafting in
unprotected left main stem stenosis</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><issue>5</issue><fpage>538</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">21272743</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Rihal</surname><given-names>CS</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Roger</surname><given-names>VL</given-names></name><name><surname>Bell</surname><given-names>MR</given-names></name><name><surname>Lennon</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Mortality differences between men and women after percutaneous
coronary interventions: 12-year, single-center experience</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><issue>24</issue><fpage>2313</fpage><lpage>2320</lpage><pub-id pub-id-type="pmid">18549915</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>A</given-names></name><name><surname>Chiasson</surname><given-names>M</given-names></name><name><surname>Buth</surname><given-names>K</given-names></name><name><surname>Hirsch</surname><given-names>G</given-names></name></person-group><article-title>Women have worse long-term outcomes after coronary artery bypass
grafting than men</article-title><source>Can J Cardiol</source><year>2005</year><volume>21</volume><issue>9</issue><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">16082435</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Zucker</surname><given-names>D</given-names></name><name><surname>Passamani</surname><given-names>E</given-names></name><name><surname>Peduzzi</surname><given-names>P</given-names></name><name><surname>Takaro</surname><given-names>T</given-names></name><name><surname>Fisher</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Effect of coronary artery bypass graft surgery on survival:
overview of 10-year results from randomised trials by the Coronary Artery
Bypass Graft Surgery Trialists Collaboration</article-title><source>Lancet</source><year>1994</year><volume>344</volume><issue>8922</issue><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">7914958</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhlbaier</surname><given-names>LH</given-names></name><name><surname>Pryor</surname><given-names>DB</given-names></name><name><surname>Rankin</surname><given-names>JS</given-names></name><name><surname>Smith</surname><given-names>LR</given-names></name><name><surname>Mark</surname><given-names>DB</given-names></name><name><surname>Jones</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Observational comparison of event-free survival with medical and
surgical therapy in patients with coronary artery disease: 20 years of
follow-up</article-title><source>Circulation</source><year>1992</year><volume>86</volume><issue>5 Suppl.</issue><fpage>II198</fpage><lpage>II204</lpage><pub-id pub-id-type="pmid">1424000</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>CM</given-names></name><name><surname>Christiansen</surname><given-names>EH</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Serruys</surname><given-names>PW</given-names></name></person-group><article-title>The EXCEL and NOBLE trials: similarities, contrasts and future
perspectives for left main revascularisation</article-title><source>EuroIntervention</source><year>2015</year><volume>11</volume><issue>Suppl V</issue><fpage>V115</fpage><lpage>V119</lpage><pub-id pub-id-type="pmid">25983143</pub-id></element-citation></ref></ref-list></back></article>